Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 10/20 | 1.00 |
| ▸ | BRD4 | O60885 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629696 | 0.83 | CREBBP (0.71) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL9629512 | 0.83 | BRD4 (0.71) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL10353037 | 0.79 | BRD4 (0.66) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL8853841 | 0.79 | MEN1 (1.00) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL11069336 | 0.79 | BRD4 (0.66) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL8853794 | 0.79 | BRD4 (0.65) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL9629698 | 0.78 | CREBBP (0.64) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL9817819 | 0.78 | ALDH1A1 (1.00) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL9629427 | 0.77 | CREBBP (0.62) | CREBBPBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL8853387 | 0.76 | BRD4 (0.61) | CREBBPBRD4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-0657407-B1 | Process for the preparation of 3-fluoro-4,6-dichlorotoluene | BAYER AG (DE) | 1997-12-10 | — | — | EP | disclosed |
| US-5475164-A | Process for preparing 3-fluoro-4,6-dichlorotoluene | BAYER AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0657407-A1 | Process for the preparation of 3-fluoro-4,6-dichlorotoluene | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| US-5105036-A | Friedel-Crafts catalyst and oxy-substituted cyclic amidines as cocatylsts; preferential formation of p-isomer | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| EP-0324181-B1 | PROCESS FOR THE PREPARATION OF BENZOTHIAZEPINONE DERIVATIVES | BAYER AG (DE) | 1991-11-27 | — | — | EP | disclosed |
| US-4948886-A | Process for the preparation of benzothiazepinone derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1990-08-14 | — | — | US | disclosed |
| EP-0292824-B1 | PROCESS FOR THE NUCLEAR CHLORINATION OF AROMATIC HYDROCARBONS | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4851596-A | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0324181-A1 | Process for the preparation of benzothiazepinone derivatives | BAYER AG (DE) | 1989-07-19 | — | — | EP | disclosed |
| EP-0292824-A1 | Process for the nuclear chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | CREBBP 3123/4885BRD4 3655/4885MEN1 1673/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | CREBBP 3251/4885BRD4 2092/4885MEN1 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.